Mobilization of Peripheral Blood Stem Cells with Paclitaxel and rhG-CSF in High-Risk Breast Cancer Patients
| Autor: | Herbert B. Herscowitz, Edmund A. Gehan, Marc E. Lippman, Mitchell S. Cairo, Kenneth R. Meehan, Areman Em, Mark Ebadi, Rebecca Slack |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Paclitaxel medicine.medical_treatment Immunology Antigens CD34 Breast Neoplasms Peripheral blood mononuclear cell Leukocyte Count Autologous stem-cell transplantation White blood cell Internal medicine Granulocyte Colony-Stimulating Factor medicine Humans Clonogenic assay Peripheral Blood Stem Cell Transplantation Chemotherapy business.industry Graft Survival Hematology Leukapheresis Middle Aged Prognosis Hematopoietic Stem Cell Mobilization Recombinant Proteins Transplantation Haematopoiesis medicine.anatomical_structure Drug Therapy Combination Female business |
| Zdroj: | Journal of Hematotherapy & Stem Cell Research. 11:415-421 |
| ISSN: | 1525-8165 |
| DOI: | 10.1089/152581602753658600 |
| Popis: | Preclinical studies have demonstrated the rapid and efficient mobilization of hematopoietic peripheral blood stem cells (PBSC) in a mouse model using the combination of paclitaxel with recombinant human granulocyte colony-stimulating factor (rhG-CSF). On the basis of these results, a clinical trial was initiated using rhG-CSF with paclitaxel for PBSC mobilization in high-risk breast cancer patients. The mobilized PBSC were evaluated for CD34(+) cell number, mononuclear cell content, and clonogenic potential. One-hundred and seventeen breast cancer patients received paclitaxel (300 mg/m(2)) administered as a 24-h continuous intravenous infusion. Forty-eight hours after completing paclitaxel, rhG-CSF (5 microg/kg) was initiated and continued until completion of PBSC collection. Leukapheresis was initiated once the white blood cell count reached 1.0 x 10(9)/L. Each collection was evaluated for the numbers of mononuclear cells (MNC) and CD34(+) cells. Clonogenic potential was enumerated using colony-forming units-granulocyte-macrophage (CFU-GM) and burst-forming units-erythroid (BFU-E). Patients receiving paclitaxel with rhG-CSF mobilized a large number of mononuclear cells/apheresis (mean, 3.7 x 10(8); range, 3.3-4.1) and CD34(+) cells/apheresis (mean, 7.2 x 10(6); range, 6.1-8.4). The average number of leukophereses needed was 1.8 (mean, range 1.6-2.0). Colony growth was normal with 178.9 x 10(5) and 214.8 x 10(5) colonies counted in CFU-GM and BFU-E assays, respectively. Patients engrafted platelets and neutrophils on day 10 following transplantation. In conclusion, PBSC mobilization with paclitaxel and rhG-CSF results in a large number of mononuclear cells and CD34(+) cells with normal clonogenic potential. The cells engraft normally following high-dose chemotherapy and autologous stem cell transplantation in high-risk breast cancer patients. These results demonstrate that paclitaxel with rhG-CSF is an efficient mobilizing agent in high-risk breast cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|